Exogenous D-β-hydroxybutyrate Lowers Blood Glucose in Part by Decreasing the Availability of L-alanine for Gluconeogenesis
Overview
Affiliations
Background: Interventions that induce ketosis simultaneously lower blood glucose and the explanation for this phenomenon is unknown. Additionally, the glucose-lowering effect of acute ketosis is greater in people with type 2 diabetes (T2D). On the contrary, L-alanine is a gluconeogenic substrate secreted by skeletal muscle at higher levels in people with T2D and infusing of ketones lower circulating L-alanine blood levels. In this study, we sought to determine whether supplementation with L-alanine would attenuate the glucose-lowering effect of exogenous ketosis using a ketone ester (KE).
Methods: This crossover study involved 10 healthy human volunteers who fasted for 24 h prior to the ingestion of 25 g of d-β-hydroxybutyrate (βHB) in the form of a KE drink (ΔG ) on two separate visits. During one of the visits, participants additionally ingested 2 g of L-alanine to see whether L-alanine supplementation would attenuate the glucose-lowering effect of the KE drink. Blood L-alanine, L-glutamine, glucose, βHB, free fatty acids (FFA), lactate and C-peptide were measured for 120 min after ingestion of the KE, with or without L-alanine.
Findings: The KE drinks elevated blood βHB concentrations from negligible levels to 4.52 ± 1.23 mmol/L, lowered glucose from 4.97 ± SD 0.39 to 3.77 ± SD 0.40 mmol/L, and lowered and L-alanine from 0.56 ± SD 0.88 to 0.41 ± SD 0.91 mmol/L. L-alanine in the KE drink elevated blood L-Alanine by 0.68 ± SD 0.15 mmol/L, but had no significant effect on blood βHB, L-glutamine, FFA, lactate, nor C-peptide concentrations. By contrast, L-alanine supplementation significantly attenuated the ketosis-induced drop in glucose from 28% ± SD 8% to 16% ± SD 7% (p < .01).
Conclusions: The glucose-lowering effect of acutely elevated βHB is partially due to βHB decreasing L-alanine availability as a substrate for gluconeogenesis.
Ozcan E, Yu K, Dinh L, Lum G, Lau K, Hsu J Nat Commun. 2025; 16(1):987.
PMID: 39856104 PMC: 11759687. DOI: 10.1038/s41467-025-56091-7.
Exogenous Ketones in Cardiovascular Disease and Diabetes: From Bench to Bedside.
Kansakar U, Nieves Garcia C, Santulli G, Gambardella J, Mone P, Jankauskas S J Clin Med. 2024; 13(23).
PMID: 39685849 PMC: 11642481. DOI: 10.3390/jcm13237391.
Clinical research framework proposal for ketogenic metabolic therapy in glioblastoma.
Duraj T, Kalamian M, Zuccoli G, Maroon J, DAgostino D, Scheck A BMC Med. 2024; 22(1):578.
PMID: 39639257 PMC: 11622503. DOI: 10.1186/s12916-024-03775-4.
Kackley M, Buga A, Brownlow M, OConnor A, Sapper T, Crabtree C PLoS One. 2024; 19(8):e0293670.
PMID: 39150916 PMC: 11329152. DOI: 10.1371/journal.pone.0293670.
Ozcan E, Yu K, Dinh L, Lum G, Lau K, Hsu J bioRxiv. 2024; .
PMID: 39131354 PMC: 11312565. DOI: 10.1101/2024.07.31.606041.